shortagewatch

Home / Companies / Pharmascience

Company family · HQ CA

Pharmascience: medicine shortages

private

As of 2 Nov 2026, 51 Pharmascience products have a reported shortage across 1 countries, covering 32 medicines.

Products short51rank #34 of 464
Medicines32active ingredients
Countries1/16
New in 90 days11+5 vs market pace
Typical duration20 monthsmedian so far
Manufacturing98%demand-driven 0%

Where

Canada51

Which therapeutic classes

Cardiovascular system12Nervous system11Digestive tract and metabolism11Cancer and immune system7Systemic hormones3Anti-infectives3Various1Dermatologicals1Musculoskeletal system1Sensory organs1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
PharmasciencePharmascience: Manufacturing problem 48 (94%)94%Pharmascience: Active ingredient shortage 1 (2%)Pharmascience: Not stated 2 (4%)All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

01235Dec: 3Jan ’25: 0Feb: 0FebMar: 1Apr: 0May: 0MayJun: 0Jul: 0Aug: 3AugSep: 4Oct: 1Nov: 1NovDec: 0Jan ’26: 0Feb: 0FebMar: 1Apr: 0May: 1MayJun: 1Jul: 1Aug: 4AugSep: 4Oct: 2Nov: 1Nov

Long-run trend in Canada

Canada dashboard
02505007501,0002017: 56420172018: 29120182019: 22320192020: 2120202021: 3220212022: 7720222023: 9320232024: 7920242025: 8420252026: 512026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Pharmascience51

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Pharmascience: 51 / 32Pharmascience

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Ranitidine423 Oct 2019Manufacturing problem1/16
Atomoxetine315 Sep 2025Manufacturing problem11/16
Atorvastatin33 Aug 2025Manufacturing problem11/16
Cinacalcet319 Dec 2024Manufacturing problem11/16
Irbesartan and Diuretics314 Nov 2022Manufacturing problem4/16
Pirfenidone323 May 2024Manufacturing problem6/16
Betahistine23 Oct 2022Manufacturing problem5/16
Esomeprazole229 Oct 2025Manufacturing problem9/16
Imatinib214 Nov 2021Manufacturing problem6/16
Metformin2not givenNot stated8/16
Rabeprazole214 Nov 2021Manufacturing problem5/16
Valproic Acid226 Jan 2022Manufacturing problem10/16
Anastrozole119 Sep 2025Manufacturing problem5/16
Busulfan126 Jun 2026Manufacturing problem3/16
Colestyramine115 Sep 2023Manufacturing problem6/16
Deferasirox110 Mar 2026Manufacturing problem8/16
Desonide120 Aug 2026Active ingredient shortage1/16
Diclofenac118 Apr 2024Manufacturing problem3/16
Digoxin16 Oct 2026Manufacturing problem2/16
Fluconazole125 Sep 2026Manufacturing problem12/16
Hydrochlorothiazide131 Aug 2026Manufacturing problem3/16
Lithium123 Oct 2023Manufacturing problem3/16
Losartan and Diuretics11 Nov 2026Manufacturing problem4/16
Methylphenidate122 May 2026Manufacturing problem9/16
Mirtazapine129 May 2023Manufacturing problem10/16
Moxifloxacin14 Oct 2026Manufacturing problem1/16
Nitrofurantoin121 Aug 2026Manufacturing problem5/16
Omeprazole128 Feb 2019Manufacturing problem8/16
Pravastatin13 Sep 2026Manufacturing problem6/16
Sotalol13 Sep 2024Manufacturing problem2/16
Tenofovir Disoproxil116 Sep 2026Manufacturing problem6/16
Topiramate121 Aug 2026Manufacturing problem8/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.